NCT07099235

Chart Review of Patients Undergoing Ketamine Treatments for Depression

Retrospective Chart Review of Patients Undergoing Intravenous Ketamine Treatments for Treatment-resistant Depression

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 250 (actual)
• Sponsor: Sunnybrook Health Sciences Centre · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Conditions

• Depression - Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	ketamine hydrochloride	Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.

Timeline

• Start date: 2022-04-01
• Primary completion: 2025-06-29
• Completion: 2025-06-29
• First posted: 2025-08-01
• Last updated: 2025-08-01

Locations

1 site across 1 country: Canada